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I n t r o d u c t i o n.  The aim of the study was to evaluate the results of postoperative radiotherapy combined with 5-fluoroura-
cil in patients with rectal cancer, with particular reference to tolerance of treatment.
M a t e r i a l  a n d  m e t h o d s.  The study group included 64 patients treated between the years 1991 and 1995 at the Depart-
ment of Oncology and Radiotherapy, Medical University of Gdaƒsk. All patients received postoperative irradiation to the pe-
lvis. Treatment schedule included two parallel opposite fields, a total dose of 45 Gy in 23–25 fractions, and concomitant 5-flu-
orouracil chemotherapy during the first three and the last three days of irradiation.
R e s u l t s.  Median follow-up for the entire group was 37 months (11–60 months). Major early complications included
diarrhoea (58%), leucopoenia (33%), nausea and vomiting (16%), dysuria (6%) and anaemia (5%). In total, acute side ef-
fects occurred in 43 patients (67%,) in 18 of them (28%) reaching grade 3–5. One patient died due to postradiation ileus and
3 patients did not complete treatment due to exacerbation of side effects and/or deterioration of their performance status. La-
te complications, mainly from bowels and urinary bladder, occurred in 22 patients (34%) and in 7 of them (11%) were seve-
re. The actuarial five year survival in the entire group was 54%. Local recurrence occurred in 15 patients (23%) and distant
metastases in 18 patients (28%).
C o n c l u s i o n.  Our method of postoperative radiochemotherapy in rectal cancer was accompanied by a large number of acu-
te and late complications and did not secure satisfactory local control. Literature data demonstrates that better tolerance of
treatment may be achieved with the use of special techniques, which decrease small bowel volume in the irradiation field. The-
re are also strong arguments in favour of replacing postoperative irradiation by preoperative radiotherapy.
Pooperacyjna radioterapia skojarzona z 5-fluorouracylem
u chorych na raka odbytnicy
W s t ´ p.  Celem pracy by∏a ocena odleg∏ych wyników leczenia uzupe∏niajàcego z udzia∏em radioterapii skojarzonej z 5-fluoro-
uracylem, ze szczególnym uwzgl´dnieniem tolerancji leczenia, u chorych po radykalnym zabiegu operacyjnym z powodu ra-
ka odbytnicy.
M a t e r i a ∏  i m e t o d y.  Przedmiotem oceny by∏o 64 chorych leczonych w Klinice Onkologii i Radioterapii Akademii Medycz-
nej w Gdaƒsku w latach 1991–1995. Wszyscy chorzy po zabiegu operacyjnym otrzymali uzupe∏niajàce napromienianie na oko-
lic´ miednicy ma∏ej technikà 2 pól przeciwstawnych do dawki ca∏kowitej 45 Gy w 23–25 frakcjach, skojarzone z podawaniem
5-fluorouracylu przez trzy pierwsze i trzy ostatnie dni napromieniania.
W y n i k i.  Mediana czasu obserwacji dla ca∏ej grupy wynosi∏a 37 miesi´cy (11–60 miesi´cy). G∏ównymi wczesnymi powik∏a-
niami w czasie leczenia by∏y biegunki (58%), leukopenia (33%), nudnoÊci i wymioty (16%), objawy dyzuryczne (6%) i nie-
dokrwistoÊç (5%). Do ostrych powik∏aƒ dosz∏o ogó∏em u 43 chorych (67%), w tym u 18 (28%) mia∏y one charakter ci´˝ki (sto-
pieƒ 3–5). Jedna chora zmar∏a w nast´pstwie niedro˝noÊci, a troje kolejnych chorych nie ukoƒczy∏o leczenia z powodu nasi-
lonych objawów niepo˝àdanych lub pogorszenia stanu ogólnego. Póêne powik∏ania, przede wszystkim w obr´bie jelit i dróg
moczowych, wystàpi∏y ogó∏em u 22 chorych (34%), w tym u 7 (11%) – w stopniu ci´˝kim. Oszacowane pi´cioletnie prze˝y-
cie w badanej grupie wynosi∏o 54%. Do wznowy miejscowej dosz∏o u 15 chorych (23%), natomiast przerzuty odleg∏e wystà-
pi∏y u 18 chorych (28%).
Po d s u m o w a n i e.  Stosowana przez nas metoda pooperacyjnego leczenia raka odbytnicy jest zwiàzana z du˝ym ryzykiem
wczesnych i póênych powik∏aƒ oraz niezadowalajàcym odsetkiem wyleczeƒ miejscowych. Dane z piÊmiennictwa wskazu-
1 Department of Oncology and Radiotherapy, 
Medical University of Gdaƒsk
2 Regional Oncological Outpatient Clinic, Gdaƒsk, Poland
346
Carcinoma of the rectum is one of the most common ma-
lignancies in Poland, estimated to afflict some 4500 per-
sons every year [1]. Radical surgery is considered to be
standard management of this malignancy.
Prognosis for the patients who undergo radical resec-
tion depends mostly on the stage according to Dukes'
classification or its modifications. Results of treatment
in patients with early stages of rectal carcinoma are satis-
factory, but in more advanced cases (Dukes' stage B and
C) local recurrence occurs in 35-50% of patients [2, 3].
The tendency to develop local recurrence of rectal cancer
is determined by the characteristic anatomical features
of this organ such as: lack of serosa in its lower, extrape-
ritoneal fragment and close vicinity of other pelvic or-
gans, which limits resectability of tumor with safe margins
of healthy tissues [3]. Local recurrence of rectal cancer
not only shortens overall survival, but also worsens the qu-
ality of life.
Therefore different forms of combined treatment
have been investigated in patients with a high risk of re-
currence for nearly 30 years. Results of extensive, ran-
domised clinical trials have proven that in this group of
patients postoperative radiotherapy combined with che-
motherapy results in a 10-20% reduction of local recur-
rence risk and prolongs overall survival [4–6]. On this ba-
sis American National Institute of Health recommended
this form of combined treatment as a routine procedure
in locally advanced rectal cancer in 1990 [7]. The above
recommendations where introduced in the Department of
Oncology and Radiotherapy of the Medical University
of Gdaƒsk in 1991. The aim of this publication is to pre-
sent our results of combined treatment in patients with
advanced rectal cancer.
Material and methods
Between 1991–1995, 64 patients received adjuvant treatment in
the Department of Oncology and Radiotherapy in Gdaƒsk after
potentially curative resection of rectal cancer (Tab. I). Adju-
vant radiochemotherapy was administrated to all patients with
tumour located in the rectum or sigmo-rectal juncture. Dukes'
stage B and C was diagnosed in 33 and 31 patients respectively.
In most patients there was no precise information concerning
the distance between inferior edge of the tumour and the anal
verge, therefore the above localisation of tumour was the only
accepted anatomical criterion to implement adjuvant treat-
ment. All patients underwent radical surgical procedure: 37
according to Miles' method, 26 to Dixon's and 1 to Hartmann's.
Patients were referred to adjuvant treatment along with general-
ly accepted rules. Low performance score (3 or 4), advanced age
and other individual risk factors were relative contraindica-
tions to radiotherapy, but such situations were exceptional.
Average age in the group was 61 years (range: 31–77 years).
Predominant pathological grades were G1 and G2. In 32 pa-
tients the time between surgery and the onset of radiotherapy
was shorter than 6 weeks, in 28 patients it was between 6 and 12
weeks and in four patients it was longer than 12 weeks (median
54 days, range 19–109 days). Patients received pelvic radiation
therapy delivered by a cobalt-60 machine or linear accelerator
with photon energy of 9 MeV. Two AP-PA parallel opposed
field technique was used. The superior border of the radiation
field was above the fifth lumbar vertebral body, and the inferior
field margin was below the obturator foramina. The lateral
borders were 1.5 cm lateral to the widest bony margin of the
true pelvic sidewalls. Most of the patients were treated to a to-
tal dose of 45 Gy calculated to the encompassing isodose in
23–25 fractions (range between 16 and 57 Gy), i.e. 47.6 Gy to
the reference ICRU point (half of IPD). Fraction dose was be-
tween 1.8 and 1.96 Gy. The dose of 450 mg/m2 of 5-fluorouracil
was administrated during the first three and the last three frac-
tions of radiotherapy. During the period covered by this analy-
sis patients did not receive chemotherapy neither before nor
after the course of radiotherapy. Median follow-up was 37 mon-
ths (range 11–60 months). The following factors were included
in the survival analysis: type of surgery, pathological grade, sta-
ge according to Dukes' classification, number of involved lymph
nodes, encompassing dose, maximal dose, fraction dose, breaks
in radiotherapy, chemotherapy schedule and dose of 5-fluoro-
uracil. Treatment side effects were evaluated according to
WHO classification. Overall and local recurrence-free survi-
vals were assessed with the Kaplan-Meier method. Log-rank
test was used to compare survival curves. Multivariate analysis
was performed by Cox proportional hazard model. Appropria-
te hazard ratios and their 95% confidence intervals were re-
ported for significant variables in final multivariate model. Hy-
pothesis testing was based on commonly accepted level of type
I error, α=0.05.
jà, ˝e tolerancj´ leczenia mo˝na poprawiç stosujàc techniki zmniejszajàce obj´toÊç jelita cienkiego w polu napromieniania.
Szereg argumentów uzasadnia tak˝e celowoÊç zastàpienia napromieniania pooperacyjnego napromienianiem przedopera-
cyjnym.
Key words: rectal cancer, postoperative radiochemotherapy
S∏owa kluczowe: rak odbytnicy, pooperacyjna radiochemioterapia
Tab. I. Patients’ characteristics
Sex Females 33 (52%)
Males 31 (48%)
Age <40 3 (5%)
41-50 9 (14%)
51-60 9 (14%)
61-70 33 (52%)
>71 10 (15%)
Dukes' stage B 33 (52%)
C 31 (48%)
Grade G1 36 (56%)
G2 24 (38%)
G3 4 (6%)
Type of surgery APR (Miles) 37 (57%)
AR (Dixon) 26 (41%)
Hartmann 1 (2%)
Time from surgery to radiotherapy <6 weeks 32 (50%)
6-12 weeks 28 (44%)
>12 weeks 4 (6%)
Radiotherapy dose <45 Gy 56 (88%)
>45 Gy 8 (12%)
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Results
E a r l y  c o m p l i c a t i o n s  o f  r a d i o t h e r a p y
Early radiotherapy complications were observed in 43 pa-
tients (67%, Tab. II). Grade 1–2 and grade 3–5 toxicity
occurred in 40% and 28% of patients, respectively. The
most frequent were gastrointestinal complications: diarr-
hoea occurred in 37 cases, and nausea and vomiting – in
10 patients. Leukopoenia and anaemia were recorded
in 21 and 3 patients, respectively and urinary symptoms –
in 4 patients. One patient experienced fatal complications:
during radiation treatment (after a dose of 36 Gy), intesti-
nal obstruction developed and was the cause of death,
despite adequate surgical management. Three patients
did not comply with the prescribed treatment – one due to
intestinal obstruction requiring surgical intervention, one
due to protractive diarrhoea, and one due to consent with-
drawal. Two other patients diagnosed with obstruction
during radiotherapy completed their treatment after reso-
lution of symptoms. Full chemotherapy dose (given in the
first three and the last three days of radiotherapy) was
administered to 47 patients, the remaining patients were
not able to comply with chemotherapy given in the last
three days due to early radiotherapy toxicity.
L a t e  c o m p l i c a t i o n s  o f  r a d i o t h e r a p y
Late radiotherapy complications were observed in 22 out
of 64 patients (34%). Most of the complications (19%)
were related to gastrointestinal toxicity (Tab. III). Diarr-
hoea of less than five stools in 24 hours (grade 1) was
observed in 11 patients, and in 1 patient grade 2 was re-
corded (more than five stools/24 hours). Six patients expe-
rienced intestinal obstruction requiring surgical interven-
tion. No patient died due to obstruction. In one patient,
recto-vaginal fistula developed and was treated surgically.
This patient died three months after surgery due to tumo-
ur recurrence. Mild urinary symptoms – frequent or pain-
ful voiding – were observed in five patients and resolved
after typical symptomatic treatment.
O v e r a l l  s u r v i v a l
Five-year actuarial survival probability was 54% (Fig.
1). In univariate analysis, Dixon type of surgery and 5-
-fluorouracil dose (full dose vs chemotherapy given in
first three days only) were associated with better
survivals. (p=0.03 and 0.04, respectively). Only the for-
mer variable retained significance in multivariate mo-
del (p=0.03, Tab. IV). Out of 37 patients who had un-
dergone abdomino-perineal surgery, 16 died (43%),
whereas in the group of anterior-abdominal approach
(26 patients), there were three deaths (12%, Fig. 2; the
Tab. II. Acute toxicity
Toxicity grade 1 2 3 4 5 Total number
in WHO scale of patients (%)
Diarrhoea 6 17 14 - - 37 (58%)
Leucopoenia 13 7 1 - - 21 (33%)
Nausea and vomiting 6 3 1 - - 10 (16%)
Anaemia 3 - - - - 3 (5%)
Bowel obstruction - - - 3 1 4 (6%)
Dysuria 4 - - - - 4 (6%)
Total* (%) 8 (13%) 17 (27%) 14 (22%) 3 (5%) 1 (1%) 43 (67%)
* in a number of patients several acute reactions were observed 
Tab. III. Late toxicity
Toxicity grade in WHO grade 1 2 3 4 Total
Intestinal complications 11 1 6 1 19 (30%)
Dysuria 3 2 - - 5 (8%)
Total* 13 2 6 1 22 (34%)
*in a number of patients several late reactions were observed
Fig. 1. Overall survival
Fig. 2. Overall survival according to type of surgery
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only patient treated with Hartmann procedure was
excluded from the analysis). Both in the univariate
(p=0.30) and the multivariate analysis (p=0.18 – ini-
tial model), stage did not appear to influence survival
significantly.
Tr e a t m e n t  f a i l u r e s
Local recurrence was observed in 15 patients (23%). Me-
an time to recurrence was 20 months (range: 4–31, fig. 3).
Higher radiotherapy dose was associated with better re-
currence-free survival in univariate analysis (p=0.046 for
dose at minimal target dose and p=0.06 for maximal tar-
get dose, Tab. V). Eleven out of 37 patients (30%) tre-
ated, with Miles’ resection experienced a relapse, as com-
pared with 4 out of 26 patients (15%) treated with Di-
xon's type of surgery (p=0.09). Probability of local
recurrence-free survival according to the type of surgery is
shown in Fig. 4 (the only patient treated with Hartmann
procedure was excluded from the analysis). In the multi-
variate model, both radiotherapy dose and type of surge-
ry appeared to be significant prognostic factors for local
relapse-free survival (p<0.01 and p=0.039, respectively,
Tab. V).
Out of 64 patients, disease dissemination was obse-
rved in 18 (28%). Mean time from the date of surgery
to diagnosis of metastatic spread was 16 months (range: 3-
–39). Liver (14 patients), lung (2 patients) and bone (2 pa-
tients) were the sites of distant recurrence. In one case
metastatic disease was found both in liver and paraaortic
lymph nodes. No significant variable determining distant
relapse-free survival was found in respective univariate or
multivariate models.
Discussion
Combined radiochemotherapy after radical surgical
resection is considered a standard treatment in patients
with rectal cancer of stage B and C. This policy is based
on the results of extensive randomised clinical trials in
which patients received adjuvant pelvic irradiation combi-
ned with simultaneous chemotherapy [4–6]. The regimen
used in these trials included semustine and 5-fluorouracil
given before and/or after radiotherapy. The following
studies showed that semustine neither improved the re-
sults of treatment nor was well tolerated and the admini-
stration of this drug was abandoned [8]. Currently preope-
Tab. IV. Univariate and multivariate analysis of overall survival
Univariate analysis, Multivariate analysis Multivariate analysis
Variable p – initial model, p – final model, p
– hazard ratio, HR
(95% confidence interval)
Gender 0.98 0.52
Age 0.38 0.41
Type of surgery a 0.03 0.01 0.03; HR = 0.26 (0.08-0.90)
Stageb 0.30 0.18
Gradec 0.60 0.77
Nodal involvement 0.33 0.31
Time from surgery to RT 0.72 0.66
Minimal RT dose 0.89 0.31
Maximal RT dose 0.47 0.25
Dose per fraction 0.77 0.24
Radiotherapy delay 0.73 0.30
Chemotherapyd 0.94 0.86
5-FU Dose 0.04 0.09
a – Miles vs Dixon
b – B2 vs C
c – G1 vs G2 vs G3
d – according to treatment plan (day 1, 2, 3, 23, 24, 25 of RT) vs no
Fig. 3. Local relapse-free survival
Fig. 4. Local relapse-free survival according to type of surgery
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rative radiotherapy is preferred by many authors. The
question whether this method is better than postoperati-
ve radiation and whether preoperative combined radio-
chemotherapy is better than preoperative radiotherapy
alone has been addressed in the ongoing 4-arm EORTC
trial number 22921. Recent introduction of total mesorec-
tal resection technique resulted in considerable decrease
of local recurrences [9, 10]. With this technique local con-
trol is so satisfactory that some authors question the need
of any adjuvant treatment. This issue is the subject of
a randomised trial which has begun recently in Holland.
In our series 5-fluorouracil was administrated only du-
ring the first and the last three days of radiotherapy. No-
wadays, chemotherapy is also given routinely before and
after radiotherapy, according to the recommendations of
American National Institute of Health.
Local recurrence was observed in 15 of 64 patients
(23%) in our group, considerably more often than in the
mentioned above GITSG and NCCTG trials (11% and
14% of patients respectively). Also in other studies the re-
currence rate was usually lower than in our study. It is
stressed that the radicality of surgery is the most impor-
tant therapeutic factor determining local control [3]. The-
refore, a relatively high recurrence rate observed in our
patients may be caused by the fact that they were opera-
ted in centres characterised by a varied experience in rec-
tal cancer treatment. Other factors determining higher
recurrence rate include: greater depth of tumour inva-
sion and the infiltration of the periintestinal fatty tissue
[11], greater lymph node involvement, higher pathological
grade and lower performance status [3]. Surgical skills,
especially in total mesorectal resection and presence of
cancer cells in a radial margin, are supposed to be another
important factors influencing local recurrence [10, 12].
In our series multivariate analysis has shown that the type
of surgery and dose of radiation were the only indepen-
dent factors associated with local control. In our group,
the frequency of local recurrences in patients who had
abdomino-perineal resection was doubled, as compared
with those who had abdominal anterior resection. This
difference was statistically significant in the multivariate
analysis. The type of surgical resection is closely determi-
ned by tumour location in the rectum, so it appears that
its more inferior location indicates poorer prognosis.
Worse outcome of Miles' procedure was also demonstra-
ted in GITSG and NCCTG trials. In the former Miles'
procedure was connected with significantly shorter time to
recurrence and in the latter it had substantial influence on
survival. However, in some studies the results of treat-
ment were comparable after both types of operation, or
even better after Miles' procedure [12-14]. The radiation
dose was another factor influencing the results of treat-
ment in our group. Since in only eight patients the ra-
diation dose exceeded 45 Gy, the importance of this fac-
tor has to be judged with great caution despite its high sta-
tistical significance.
Due to the retrospective type of our study and since
not all patients were followed-up in oncological centres, it
appeared impossible to determine the total number of
perineal recurrences. This question seems to be particu-
larly relevant, because the inferior border of the irradia-
tion field lay below the obturator foramina, therefore it
did not encompass the perineum. Some authors recom-
mend a routine irradiation of this region, even though
such an extended field is connected with higher risk of ra-
diation side effects.
Distant metastases were detected in 18 of our pa-
tients (28%). In GITSG and NCCTG trials dissemina-
tion occurred in 26% and 29% respectively; significantly
more often in cases of deep intestinal infiltration and po-
sitive lymph nodes. In our group, probably due to a small
number of patients, these relations were not confirmed in
multivariate analysis.
Actuarial five – year survival was observed in 54% of
our patients, similarly to the outcome in the mentioned
above trials (respectively 57% and 53%). The type of sur-
Tab. V.  Local relapse-free survival
Univariate analysis, Multivariate analysis Multivariate analysis
Variable p - initial model, p p - final model, p
- hazard ratio, HR
(95% confidence interval)
Gender 0.45 0.82
Age 0.78 0.98
Type of surgerya 0.09 0.044 0.039; HR=0.29 (0.09-0.94)
Stageb 0.67 0.29
Gradec 0.51 0.90
Nodal involvement 0.55 0.64
Time from surgery to radiotherapy 0.37 0.50
Minimal RT dose 0.046 0.94 0.009; HR=0.98 (0.96 - 0.99)
Maximal RT dose 0.06    0.65 
Dose per fraction 0.55 0.53
Radiotherapy delay 0.12 0.17
Chemotherapyd 0.99 0.95
5-FU dose 0.48 0.72
a - Miles vs Dixon
b - B2 vs C
c - G1 vs G2 vs G3
d - according to treatment plan (day 1, 2, 3, 23, 24, 25 of RT) vs no chemotherapy on day 23, 24, 25
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gery was the only factor influencing survivals. The higher
was the stage the shorter was the survival, but the diffe-
rence did not reach statistical significance. Tumour advan-
cement is a substantial prognostic factor in most publica-
tions. The lack of its significance in our group may re-
sult from its small size, understaging of Dukes' stage C, or
incomplete resection. The analysed group of patients ca-
me from different, often small regional departments, whe-
re accurate staging was not always possible. Surgery pro-
tocols and pathological reports frequently did not include
the number of excised and examined lymph nodes.
Combined adjuvant treatment of rectal cancer is
often accompanied by a high risk of complications [2,
15]. In our study acute toxicity affected 67% of patients
and in 28% it reached a high grade (3-5). The rates and
types of acute toxicity were similar to those reported by
other authors using the same treatment. Despite a high
intensity of complications, 94% of patients completed ra-
diotherapy and 73% received a planned course of chemo-
therapy. Acute and late toxicity of adjuvant treatment of
rectal cancer mainly affects the alimentary tract. Diarrho-
ea was the most frequent toxicity caused by irradiation,
and was the result of a substantial volume of small intesti-
ne moving to the small pelvis after rectal resection [16,17].
The risk of radiation intestinal injury in postoperative re-
actions may be decreased by a replacement of the small
intestine from the irradiated pelvis [18]. Customised bloc-
king, modern multiple field techniques, computer 3-di-
mentional treatment planning and special therapeutic ta-
bles – "belly boards" – are used to accomplish this aim
[19]. Radiotherapy in the prone position with a full urina-
ry bladder is also a simple method of limiting the risk of
complications [19]. Protection of intestines is also possible
by using radioprotectors such as sucralfate [20]. Routine
evaluation of individual small intestine volume in the ra-
diation field has been conducted in our department for
some years. It allows for a modification of the field
margins in selected cases. The results of this study and
other publications encouraged us to modify our techni-
que of radiotherapy. Nowadays we employ a four field
technique, prone patient position and customised bloc-
king in all cases. We are awaiting the effects of these mo-
difications.
In recent years preoperative radiotherapy in rectal
cancer patients attracts special interest. Good tolerance of
treatment and also a chance to decrease the size of tumor,
which enables its resection and often allows a sphincter
preservation are advantages of this method [21, 22]. Pre-
operative radiotherapy gives an opportunity to decrease
the irradiated healthy tissue volume, makes treatment
planning easier, allows to avoid the risk of postsurgical tis-
sue hypoxia and decreases the risk of tumour dissemina-
tion during the surgical procedure [22]. The disadvantages
of this method are: a higher risk of radiation complica-
tions which make the operation more difficult, and tu-
mor progression during radiotherapy in case of its pri-
mary radioresistance [22]. Results of clinical trials per-
formed so far prove that preoperative radiotherapy
prolongs survival in comparison with surgery alone and is
more effective in preventing local recurrences than posto-
perative radiotherapy [23-25].
In conclusion, the outcome of postoperative radio-
chemotherapy applied in our department was unsatisfac-
tory in terms of both locoregional control and treatment
– induced toxicity. Currently there is an increasing use
of preoperative radiotherapy. This method has been used
in our department for some years, at the onset as part
of a prospective randomised clinical trial conducted by
EORTC, and recently also in a trial co-ordinated by the
Institute of Oncology in Warsaw. With a more common
use of total mesorectal excision in Poland further signifi-
cant improvement of treatment results may be expected.
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